Help
RSS
API
Feed
Maltego
Contact
Domain > www.ascletis.com
×
Welcome!
Right click nodes and scroll the mouse to navigate the graph.
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2013-05-03
184.168.254.1
(
ClassC
)
2024-10-06
47.75.123.183
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: nginxDate: Sun, 06 Oct 2024 15:44:42 GMTContent-Type: text/htmlContent-Length: 162Connection: keep-aliveLocation: https://www.ascletis.com/Strict-Transport-Security: max-age31536000 html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>nginx/center>/body>/html>
Port 443
HTTP/1.1 200 OKServer: nginxDate: Sun, 06 Oct 2024 15:44:43 GMTContent-Type: text/html; charsetutf-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingSet-Cookie: PHPSESSIDcihluu3c0a2a9f2sruffr7pe97; path/Expires: Thu, 19 Nov 1981 08:52:00 GMTPragma: no-cacheCache-control: privateX-Powered-By: ThinkCMFStrict-Transport-Security: max-age31536000 !DOCTYPE html>html langzh-CN>head> meta charsetutf-8> meta http-equivX-UA-Compatible contentIEedge> meta nameviewport contentwidthdevice-width, initial-scale1> meta nameauthor content杭州争锋网络科技有限公司-高端网站建设-http://www.zfnet.net/> meta nameapple-mobile-web-app-capable contentyes> meta nameapple-mobile-web-app-status-bar-style contentblack> meta nameformat-detection contenttelephoneno> !-- 上述3个meta标签*必须*放在最前面,任何其他内容都*必须*跟随其后! --> title>Ascletis Pharma Inc./title> meta namekeywords content歌礼,甘莱,ascletis,gannex> meta namedescription content歌礼生物科技(杭州)有限公司> !-- Bootstrap --> link relshortcut icon href/themes/simplebootx/Index/Public/images/favicon.ico typeimage/x-icon> link href/themes/simplebootx/Index/Public/css/bootstrap.min.css relstylesheet typetext/css> link relstylesheet typetext/css href/themes/simplebootx/Index/Public/css/index.css> link relstylesheet typetext/css href/themes/simplebootx/Index/Public/css/base.css> link relstylesheet typetext/css href/themes/simplebootx/Index/Public/css/vis.css> script> var _hmt _hmt || ; (function() { var hm document.createElement(script); hm.src https://hm.baidu.com/hm.js?037ea702ffd7f5ccf6caa6bc7edb502e; var s document.getElementsByTagName(script)0; s.parentNode.insertBefore(hm, s); })(); /script> !-- HTML5 shim 和 Respond.js 是为了让 IE8 支持 HTML5 元素和媒体查询(media queries)功能 --> !-- 警告:通过 file:// 协议(就是直接将 html 页面拖拽到浏览器中)访问页面时 Respond.js 不起作用 --> !--if lt IE 9> script srchttps://cdn.bootcss.com/html5shiv/3.7.3/html5shiv.min.js>/script> script srchttps://cdn.bootcss.com/respond.js/1.4.2/respond.min.js>/script> !endif-->/head>body>div classheader> div classcontainer header_box> h1 classfl>a href/>img src/themes/simplebootx/Index/Public/images/logo1s.png stylewidth: 113px;height: 36px>/a> a hrefhttps://www.gannexpharma.com target_blank>img src/themes/simplebootx/Index/Public/images/logo2s.png stylewidth: 115px;height: 36px;padding-left: 5px;>/a> /h1> div classlanguage fr>a href/Index/index/index/l/en-us.html>i>/i>EN/a>/div> div classssubNav1 fr> span idnavline_1 classnavline>/span> span idnavline_2 classnavline>/span> span idnavline_3 classnavline>/span> /div> div classnav fr> ul> /if> li class link> a href/Index/index/son/cate_id/133.html classtit link>关于歌礼/a> if condition$sub_cate$valid neq null> div classsubnav dn clearfix> !-- --> a href/single2/139.html>公司概览/a> !-- -->!-- --> a href/team/140.html>管理团队/a> !-- -->!-- --> a href/board/141.html>董事会/a> !-- -->!-- --> a href/single2/174.html>联系我们/a> !-- --> /div> /li> /if> li class link> a href/Index/index/son/cate_id/134.html classtit link>科学研究/a> if condition$sub_cate$valid neq null> div classsubnav dn clearfix> !-- --> a href/single/191.html>代谢性疾病/a> !-- -->!-- --> a href/single2/144.html>病毒性疾病/a> !-- -->!-- --> a href/single/142.html>肿瘤/a> !-- -->!-- --> a href/single2/178.html>拓展性适应症/a> !-- --> /div> /li> /if> li class link> a href/Index/index/son/cate_id/135.html classtit link>产品和研发管线/a> if condition$sub_cate$valid neq null> div classsubnav dn clearfix> !-- --> a href/single/145.html>研发管线/a> !-- -->!-- --> a href/single/146.html>产品/a> !-- -->!-- --> a href/single/177.html>患者招募/a> !-- --> /div> /li> /if> li class > a href/single3/136.html classtit link>战略合作/a> if condition$sub_cate$valid neq null> div classsubnav dn clearfix> /div> /li> /if> li class link> a href/Index/index/son/cate_id/137.html classtit link>投资者关系/a> if condition$sub_cate$valid neq null> div classsubnav dn clearfix> !-- --> a href/Index/index/relation/cate_id/150.html>财务及申报信息/a> !-- -->!-- --> a href/Index/index/relation/cate_id/173.html>推介材料/a> !-- --> /div> /li> /if>li class> a href/Index/index/son/cate_id/154.html classtit link>新闻/a> /li> /li> /if> li class > a href/single3/138.html classtit link>加盟歌礼/a> if condition$sub_cate$valid neq null> div classsubnav dn clearfix> /div> /li> /if> /ul> /div> /div> div classnav-bg dn>/div>/div>!-- banner -->div classbanner> div classflexslider> ul classslides> li> img src/themes/simplebootx/Index/Public/images/banner1.jpg /> img src/themes/simplebootx/Index/Public/images/banner_sj1.jpg alt> div classshow_bg one3> img src/themes/simplebootx/Index/Public/images/bg3.png> div classshoe_center> div classskew> div classskew_main>因治愈而自由/div> /div> p>成为最具创新力的世界级生物医药公司, 致力于病毒性疾病、代谢性疾病、肿瘤(口服肿瘤代谢检查点与免疫检查点抑制剂) 等领域的研发和商业化,满足国内外患者临床需求。/p> /div> /div> /li> li>img src/themes/simplebootx/Index/Public/images/banner2.jpg /> img src/themes/simplebootx/Index/Public/images/banner_sj2.jpg alt> div classshow_bg one2> img src/themes/simplebootx/Index/Public/images/bg2.png> div classshoe_center> div classskew> div classskew_main>正 · 勇 · 纯 · 合/div> /div> p>价值观是我们一切工作的基石。/p> /div> /div> /li> li> img src/themes/simplebootx/Index/Public/images/banner3.jpg /> img src/themes/simplebootx/Index/Public/images/banner_sj3.jpg alt> div classshow_bg one1> img src/themes/simplebootx/Index/Public/images/bg1.png> div classshoe_center> div classskew> div classskew_main>汇聚治愈肝炎的中国力量/div> /div> p>到2030年,消除病毒性肝炎这一重大公共健康威胁。/p> b classclearfix>span classfr>世界卫生组织/span>i>/i>/b> /div> /div> /li> /ul> /div>/div>div classcontect> div classcontect1 clearfix> div classcontainer> h2>歌礼制药有限公司/h2> p>歌礼成立于2013年,2018年在香港证券交易所上市(1672.HK)。歌礼致力于病毒性疾病、代谢性疾病、肿瘤(口服肿瘤代谢检查点与免疫检查点抑制剂)等领域创新药的研发和商业化,以解决国内外患者临床需求。甘莱制药有限公司为歌礼制药集团旗下全资子公司,专注于MASH疾病领域创新药的研发和商业化。/p> /div> /div> div classcontect2 clearfix> div classcontainer> div classrow page_content home_boxes> div classcol-lg-6 col-md-6 col-sm-6> div classhome_box> h3>代谢性疾病/h3> div classboxContent> p>ASC30是首款也是唯一一款既可每月一次皮下注射也可每日一次口服用于治疗肥胖症的小分子GLP-1受体(GLP-1R)激动剂。/p> /div> div classbtnCenter> a classbtn hrefhttps://www.ascletis.com/single/191.html>Learn More/a> /div> /div> /div>div classcol-lg-6 col-md-6 col-sm-6> div classhome_box> h3>病毒性疾病/h3> div classboxContent> p>皮下注射PD-L1抗体ASC22有望为乙肝功能性治愈和HIV感染功能性治愈带来重大突破。/p> /div> div classbtnCenter> a classbtn hrefhttps://www.ascletis.com/single2/144.html>Learn More/a> /div> /div> /div>div classcol-lg-6 col-md-6 col-sm-6> div classhome_box> h3>肿瘤/h3> div classboxContent> p>脂肪酸合成酶口服抑制剂管线以及新一代检查点抑制剂-口服PD-L1小分子抑制剂管线。/p> /div> div classbtnCenter> a classbtn hrefhttps://www.ascletis.com/single/142.html>Learn More/a> /div> /div> /div>div classcol-lg-6 col-md-6 col-sm-6> div classhome_box> h3>拓展性适应症/h3> div classboxContent> p>痤疮:皮脂分泌依赖于脂肪酸的从头合成,在痤疮形成的过程中,皮脂分泌增多,这一步骤可被FASN抑制剂ASC40所抑制。/p> /div> div classbtnCenter> a classbtn hrefhttps://www.ascletis.com/single2/178.html>Learn More/a> /div> /div> /div> /div> /div> /div> div classcontect3 clearfix> div classcontainer> div classrow> div classcol-lg-8 col-md-8> div classvideo> div classvideo-hidden>span>/span>img srchttps://www.ascletis.com/data/upload/admin/20200115/5e1ec1241dae3.jpg classvideo-img alt>/div> !--div classivideo pcenter> div idmediaplayer data-filehttps://www.ascletis.com/data/upload/admin/20180521/5b02a0a647fe2.mp4>/div> /div>--> /div> /div> div classcol-lg-4 col-md-4 news_ri> div classcontect3_news> div classtitle>span classfl>新 闻/span>a href/Index/index/son/cate_id/154.html>更多/a>/div> /div> ul> li> a href/news_detail/181/id/1057.html> p stylewidth: 350px; overflow:hidden;white-space:nowrap; text-overflow:ellipsis;>甘莱战略合作伙伴Sagimet宣布用于治疗经肝穿活检证实纤维化2/3期MASH患者的ASC40(地尼法司他) 获得FDA突破性疗法认定/p> div classanniu>详情i>/i>/div> /a> /li>li> a href/news_detail/181/id/1044.html> p stylewidth: 350px; overflow:hidden;white-space:nowrap; text-overflow:ellipsis;>歌礼进军肥胖药物领域,宣布其小分子GLP-1R激动剂ASC30正于美国进行每月一次皮下注射和每日一次口服片剂治疗肥胖症的两项I期临床试验/p> div classanniu>详情i>/i>/div> /a> /li>li> a href/news_detail/181/id/1017.html> p stylewidth: 350px; overflow:hidden;white-space:nowrap; text-overflow:ellipsis;>甘莱宣布在欧洲肝脏研究学会2024年大会以壁报形式展示正在开展的每日一次ASC41治疗经活检证实的代谢功能障碍相关脂肪性肝炎患者52周II期临床试验的12周积极期中结果/p> div classanniu>详情i>/i>/div> /a> /li>li> a href/news_detail/181/id/1004.html> p stylewidth: 350px; overflow:hidden;white-space:nowrap; text-overflow:ellipsis;>歌礼宣布有关FXR激动剂ASC42的战略决定/p> div classanniu>详情i>/i>/div> /a> /li> !-- li> a href/news_detail/181/id/1057.html> p>甘莱战略合作伙伴Sagimet宣布用于治疗.../p> div classanniu>详情i>/i>/div> /a> /li>li> a href/news_detail/181/id/1044.html> p>歌礼进军肥胖药物领域,宣布其小分.../p> div classanniu>详情i>/i>/div> /a> /li>li> a href/news_detail/181/id/1017.html> p>甘莱宣布在欧洲肝脏研究学会2024年大.../p> div classanniu>详情i>/i>/div> /a> /li>li> a href/news_detail/181/id/1004.html> p>歌礼宣布有关FXR激动剂ASC42的战略决定/p> div classanniu>详情i>/i>/div> /a> /li>--> /ul> /div> /div> /div> /div> div classcontect4 parallax> div classcontainer contec4_box> div classrow> div classcol-lg-4 col-md-0 col-sm-0 videoLef > div classvideo> div classvideo-hidden> span styleleft: 0;>/span>img srchttps://www.ascletis.com/data/upload/admin/20211221/61c1328c2c113.png classvideo-img alt> /div> div classivideo pcenter> div idmediaplayerall data-filehttps://www.ascletis.com/data/upload/admin/20211221/61c1342de1632.mp4>/div> /div> /div> /div> div classcol-lg-8 col-md-12 col-sm-12> h3>歌礼为您提供放飞梦想的舞台/h3> p>员工是歌礼最为宝贵的财富。歌礼致力于为员工提供平等的发展机会和积极向上的工作环境,鼓励并期待员工的大胆创新。/p>p>我们的愿景是成为最具创新力的世界级生物医药公司。歌礼快速推进药物管线开发,聚焦两大临床需求尚未满足的医疗领域:代谢性疾病和病毒性疾病,并以全球化的视野进行布局。追求卓越的歌礼人正在满怀激情地为实现这一愿景而共同拼搏。/p>p>我们为员工提供具有竞争力的薪资、福利。如您有意加盟歌礼,请将简历发送至 hr@ascletis.com,/p>p>我们将尽可能地结合您的专业和公司发展需求,为您提供放飞梦想的舞台。/p> div classanniu>a href#>更多i>/i>/a>/div> /div> /div> /div> /div> /div>div classfooter pc> div classcontainer footer_box> div classrow> div classcol-sm-7 footerNav> div classrow> div classcol-sm-4> img src/themes/simplebootx/Index/Public/images/logo1.png> /div> div classcol-sm-8 textwidget clearfix> div classrow> ul classcol-md-7 col-sm-6 col-xs-6> li>a>© 2018 Ascletis Pharma Inc./a>/li> li> !--a hrefhttp://www.beian.gov.cn/portal/registerSystemInfo?recordcode33010802003344 target_blank relnofllow stylefont-size:12px;color:#b5b6b6>img src/themes/simplebootx/Index/Public/images/gongan.png stylemargin: 2px 5px 0;width: 17px;>浙公网安备 33010802003344号/a>--> /li> li stylewidth: 15px> script typetext/javascript> document.write(unescape(%3Cspan idcnzz_stat_icon_1279711163%3E%3C/span%3E%3Cscript srchttps://s4.cnzz.com/z_stat.php%3Fid%3D1279711163%26show%3Dpic1 typetext/javascript%3E%3C/script%3E)); /script> /li> /ul> ul classcol-md-5 col-sm-12 col-xs-12> li>a>All Rights Reserved/a>/li> !--li>a hrefhttp://beian.miit.gov.cn target_blank>浙ICP备 11050387号-1/a>/li>--> /ul> /div> /div> /div> /div> div classcol-sm-5 footerNav> div classrow> div classwidget_even col-sm-3> h3 classwidget_title>contact/h3> /div> div classtextwidget clearfix col-sm-9> div classrow> ul classcol-md-6 col-sm-6 col-xs-6> li>a href#>pr@ascletis.com/a>/li> li>a href#>bd@ascletis.com/a>/li> /ul> ul classcol-md-6 col-sm-6 col-xs-6> li>a href#>hr@ascletis.com /a>/li> li>a href#>clinicaltrials@ascletis.com/a>/li> /ul> /div> /div> /div> /div> /div> div styleclear:both>/div> /div>/div>div classfooter_moblie> div classcontainer> p>© 2018 Ascletis Pharma Inc. All Rights Reservedbr> a hrefhttp://www.beian.gov.cn/portal/registerSystemInfo?recordcode33010802003344 target_blank relnofllow stylefont-size:12px;color:#b5b6b6>img src/themes/simplebootx/Index/Public/images/gongan.png stylemargin: 2px 5px 0;width: 17px;>浙公网安备 33010802003344号/a> 浙ICP备11050387号-1/p> /div>/div>script typetext/javascript src//js.users.51.la/21311571.js>/script>script srchttps://cdn.bootcss.com/jquery/1.12.4/jquery.min.js>/script>script typetext/javascript src/themes/simplebootx/Index/Public/js/bootstrap.min.js>/script>script typetext/javascript src/themes/simplebootx/Index/Public/js/jquery.flexslider-min.js>/script>script src/themes/simplebootx/Index/Public/js/jwplayer/jwplayer.js>/script>script src/themes/simplebootx/Index/Public/js/jwplayer/jwpsrv.js>/script>script src/themes/simplebootx/Index/Public/js/jwplayer/jwplayer.html5.js>/script>!-- script typetext/javascript srcjs/jquery.parallax.js>/script> -->script typetext/javascript> $(function(){ $(.flexslider).flexslider({ slideshowSpeed: 4000, //展示时间间隔ms animationSpeed: 400, //滚动时间ms touch: true, //是否支持触屏滑动 }); var TonyVideo { load: function (objs) { var objplay jwplayer(mediaplayer).setup({ flashplayer: /themes/simplebootx/Index/Public/js/jwplayer/flashplay.swf, html5player: /themes/simplebootx/Index/Public/js/jwplayer/html5player.js, file: objs.vfiles, image: objs.vfimg, width: 100%, height:100%, aspectratio:16:9, stretching:fill, controls: true, autostart: objs.isautoplay }); return objplay; } } jQuery(#mediaplayer).click(function(){ var onj $(this).attr(data-file); if (onj ! ) { TonyVideo.load({ vcontainer: mediaplayer, vfiles: onj, isautoplay: true }); }; }); var TonyVideoall { load: function (objsall) { var objplay jwplayer(mediaplayerall).setup({ flashplayer: /themes/simplebootx/Index/Public/js/jwplayer/flashplay.swf, html5player: /themes/simplebootx/Index/Public/js/jwplayer/html5player.js, file: objsall.vfiles, image: objsall.vfimg, width: 100%, height:100%, aspectratio:16:9, stretching:fill, controls: true, autostart: objsall.isautoplay }); return objplay; } } $(#mediaplayerall).click(function(){ var onjall $(this).attr(data-file); console.log(onjall) if (onjall ! ) { TonyVideoall.load({ vcontainer: mediaplayerall, vfiles: onjall, isautoplay: true }); }; }); /*if ($(window).width()>767) { $(window).load(function() { $(.contect4).parallax(50%, 0.5); }) }*/ })/script>script typetext/javascript src/themes/simplebootx/Index/Public/js/index.js>/script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]